Onco Actu du 20 septembre 2017

	3. Prévention
Professor Jack Cuzick: ‘Sitting on the borders between maths and cancer medicine’ [Cancer Research UK] “I’m pleased personally of course, but it’s also really important for our field, because cancer prevention tends not to get the recognition that it should,” he says.
	3.1 Prévention - Tabac
A smoke-free generation? [BMJ] Unlikely, thanks to complacency, naivety, and impotence in the face of big tobacco.
	4.7 Dép., diag. & prono. - Col de l'utérus
HPV screening for cervical cancer – Expert Reaction [Science Media Centre] "The NZ population has a significantly higher rate of cytology detected HPV related abnormalities (HSIL) than the Compass pilot study, if HPV test sensitivity is increased as predicted the increase in colposcopy referrals will be greater than seen in the Victorian Compass study.”
HPV screening better at detecting cervical cancer than pap smear, trial shows [The Guardian] Results come less than three months before five-yearly HPV test replaces the two-yearly pap test in Australia.
	5. Traitements
Bacteria Can Make Tumors Worse [In the Pipeline] This work immediately suggests that any cancer patients receiving gemcitabine be treated with antibiotics, and I hope that this affects clinical practice quickly. You wonder how many similar stories are out there that we don’t know about yet!
Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer [NCI] Because patients treated outside clinical trials are often older and less healthy than patients who enroll in clinical studies, the “real-world” percentage of women who experience chronic neuropathy after taxane-based chemotherapy is likely higher than reported in this study, Dr. Ganz explained.
	5.12.2 Immunothérapies - CAR-T
On CAR-T’s Edge, Seattle Researchers Plot to Bypass Novartis Therapy [Xconomy] Seattle Children’s is now aiming for CAR-T therapy not for the most desperate cases, but to treat, even cure, kids earlier in the course of the disease. The decision has also left Novartis, which is charging $475,000 per treatment, with no competition for the time being.
	5.12.8 Immunothérapies - Economie
Nivolumab now available for lung cancer after company offers NICE new CDF deal [NICE] Exact treatment costs depend on a person’s weight and their type of lung cancer. For example, for someone weighing 73 kg, a month’s treatment would cost £5,268.
Life-extending lung cancer drug approved [BBC News] Scotland already offers nivolumab to people with advanced disease who have also tried chemotherapy. England's drugs watchdog had originally said nivolumab was too expensive.
ICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancers [Institute of Cancer Research] “Immunotherapies are currently very expensive, but one of the ways to make them more cost-effective is to direct them to patients most likely to respond. Today’s decision is a welcome step in the right direction in its requirement for use of the PD-L1 biomarker for some patients.”
UK backs Opdivo for lung cancer after Bristol-Myers cuts price [Reuters] The National Institute for Health and Care Excellence (NICE) said on Wednesday that about 1,300 patients with lung cancer were expected to receive the drug through the Cancer Drugs Fund as a result of the deal.
	5.2 Pharma
Armed with new data, AbbVie, Roche likely to file early for bigger Venclexta use in CLL: analyst [FiercePharma] Venclexta hit the market last year at a list price of $110,000, and it faces competition from Celgene’s megablockbuster Revlimid as well as newer entrants like Gilead Sciences’ Zydelig.
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery [Pfizer] The U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy (surgical removal of the cancer-containing kidney).
	5.3 Traitements - FDA, EMA, NICE...
Real World Evidence: FDA Commits to Advancing its Use [RAPS] To enable greater adoption of real world evidence (RWE) in clinical and regulatory decisions, FDA Commissioner Scott Gottlieb said Tuesday the agency will need to work with the healthcare system to change the way clinical information is collected.
Highlighting a major shift at the FDA, regulators put Amicus’ once-spurned drug on fast track [EndPoints] The FDA was in anything but a collaborative mood when it slammed Amicus with a major delay last fall, demanding that it conduct a Phase III study. But then came a new Trump administration and a new FDA commissioner. The implications for biopharma are huge.
	5.3.4 Traitements - AMM (FDA, EMA)
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) [Novartis] Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU.
Novartis's Rydapt wins EU approval for AML, other diseases [Reuters] Rydapt (midostaurin) was also approved for three types of advanced systemic mastocytosis, a rare disease where mast cells accumulate in the skin, bone marrow and some internal organs.
	5.6 ESMO
ESMO Press Release: ESMO announces new interim Editor-in-Chief of Annals of Oncology [ESMO] “I am pleased to announce that Professor Fabrice André is stepping in as interim Editor-in-Chief with immediate effect. His commitment to the evolution of Annals of Oncology has already been amply proven during his time as its Associate Editor."
	6. Lutte contre les cancers
Cancer patients need better care, not just more technology [Nature] In middle- and low-income countries the technology-centric approach to cancer threatens to do more harm than good.
	6.6 Publications
New Feature Alert: Two-Page ORCID Authorization Process [ORCID] This makes the authorization process clearer to our users and is consistent with the user experience on other highly-used platforms such as Google or LinkedIn.
	6.9 Controverses
'One-size-fits-all’ threshold for P values under fire [Nature] Scientists hit back at a proposal to make it tougher to call findings statistically significant.